Competitor Analysis: Anti-Infective Antibodies
| Product Code | LME00121 |
| Publication Date | November 2011 |
| Publisher | La Merie |
| Product Type | Report |
| Pages | 160 |
| ISBN Number | not applicable |
Competitor Analysis: Anti-Infective Antibodies
Product description
The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of infectious diseases as of November 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The emergence of antibiotic resistant microorganisms, lethal viruses and the threat of engineered microorganism have newly stimulated the interest in recombinant antibodies for infectious diseases. Advances in understanding pathogenetic mechanisms and new antibody technologies have further contributed to a growing class of anti-infective antibodies. Apart from recombinant mono- or polyclonal antibodies, human plasma-derived immunoglobulins have their place in the treatment of immunedeficiencies and specific immunoglobulins (hyperimmunes) are part of standard protocols in post-exposure prophylaxis of a number of infectious diseases. Modern plasma-derived immunoglobulins are characterized by improved purification procedures, more convenience (room temperature stable, ready-to-use preparations, new stabilizers, higher concentrated) and new developments.
The report includes a compilation of product portfolios and current active projects in research and development of anti-infective antibodies and immunoglobulins. In addition, the report lists company-specific R&D pipelines product portfolios anti-infective antibodies, immunoglobulins and hyperimmunes. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Contents
- Recombinant Antibodies for Viral Diseases
- Respiratory Syncytial Virus (RSV)
- Human Immune Deficiency Virus (HIV)
- Hepatitis C Virus (HCV)
- Rabies Virus
- Influenza Virus
- Herpes Simplex Virus
- Hemorrhagic Fever Viruses
- Cytomegalovirus (CMV)
- Various Viruses
- Unspecified Virus, Broad Spectrum Antiviral Antibodies
- Recombinant Antibodies for Bacterial Diseases
- Bacillus Anthracis
- Staphylococci
- Pseudomonas
- Streptococci
- Clostridium Difficile
- Clostridium Botulinum
- Various Bacteria
- Unspecified Bacteria, Broad Spectrum Antibacterial Antibodies
- Recombinant Antibodies for Parasitic Diseases
- Human Plasma-Derived Immunoglobulins
- Conventional Intravenous Immunoglobulins (IVIG)
- Enriched Immunoglobulins
- Injectable SC/IM Immunoglobulins
- Oral Immunoglobulins
- Specific Immunoglobulins (Hyperimmunes)
- Varicella Zoster Immunoglobulins (VZIG)
- Tetanus Immunoglobulins
- Rabies Immunoglobulins
- Hepatitis B Immunoglobulins
- Hepatitis A Immunoglobulins
- Cytomegalovirus Immunoglobulins
- Vaccinia Immunoglobulins
- Various Immunoglobulins
- Corporate Anti-Infective Antibody Portfolios and R&D Pipelines